Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss Three months ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Notes £’000 £’000 £’000 £’000 Product revenue, net 3 45,514 23,992 87,566 31,674 Pre-product revenue, net 3 — 3,708 — 6,537 Total revenue from sale of therapies 45,514 27,700 87,566 38,211 Collaboration revenue 3 2,250 4,302 4,739 16,265 Total revenue 47,764 32,00 ...